- Oxcarbazepine-D4
-
- $1370.00
-
2026-04-20
- CAS:1134188-71-8
- Purity:
- Supply Ability: 10g
|
| | OXCARBAZEPINE-D4 Basic information |
| Product Name: | OXCARBAZEPINE-D4 | | Synonyms: | OXCARBAZEPINE-D4;TRILEPTAL-D4;10,11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE-D4;1,2,3,4-tetradeuterio-5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide;10,11-dihydro-11-oxo-5H-dibenz[b,f]azepine-1,2,3,4-d4-5-carboxamide;9-oxo(4,5,6,7-2H?)-2-azatricyclo[9.4.0.03,?]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide;D4-Oxcarbazepine;Oxcarbazepine-6,7,8,9-d4 (Aniline-6,7,8,9-d4) | | CAS: | 1134188-71-8 | | MF: | C15H8D4N2O2 | | MW: | 256.29 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | OXCARBAZEPINE-D4 Chemical Properties |
| Boiling point | 457.236±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.329±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 13.733±0.20(predicted) |
| | OXCARBAZEPINE-D4 Usage And Synthesis |
| Description | Oxcarbazepine-d4 is intended for use as an internal standard for the quantification of oxcarbazepine by GC- or LC-MS. Oxcarbazepine is a prodrug form of the antiepileptic compound 10,11-dihydro-10-hydroxy carbamazepine . It inhibits high-frequency repetitive firing of rat spinal cord neurons when used at a concentration of 1 μM. Oxcarbazepine protects against electroshock-induced tonic hindlimb extension (ED50s = 10-20 mg/kg), as well as seizures induced by pentylenetetrazole (PTZ; ) or picrotoxin in rodents (ED50s = 23-30 and 150-250 mg/kg, respectively). Formulations containing oxcarbazepine have been used in the treatment of epileptic seizures. | | Uses | Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker[1]. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines[2]. Anti-cancer and anticonvulsant effects[2][3]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Ashley M Thomas, et al. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication ManagementJ Pain. 2018 Jan;19(1):1-9. DOI:10.1016/j.jpain.2017.08.001
[3] Ching-Yi Lee,et al. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016 May;127(3):445-53. DOI:10.1007/s11060-016-2056-6
[4] M Schmutz, et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia. 1994;35 Suppl 5:S47-50. DOI:10.1111/j.1528-1157.1994.tb05967.x |
| | OXCARBAZEPINE-D4 Preparation Products And Raw materials |
|